McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in a November 2014 online edition of the Policy and Regulatory Report (PaRR) in an article entitled, “New FTC pharma rules could see US Supreme Court review.” A dispute over industry-specific requirements issued by the Federal Trade Commission (FTC) could end up at the US Supreme Court as pharmaceutical companies fight the agency’s rulemaking powers, according to two attorneys. View the article